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CASE PRESENTATION
A 5-year-old female was referred for evaluation of
steroid-resistant nephrotic syndrome (SRNS). At 3 years
of age, her family was concerned about the proteinuria
(3þ ) and hematuria (2þ ) and brought her to the hospital
for evaluation. There was no antecedent infection, fever,
or rash. No family history of renal disease was noted, and
her parents and her elder brother were negative for
urinalysis (Figure 1a). At the initial visit, laboratory studies
revealed hypoproteinemia (serum albumin 3.1 g/100 ml)
and hyperlipidemia (total cholesterol 282 mg/100 ml),
whereas renal function was normal (serum creatinine
0.2 mg/100 ml, and an estimated glomerular filtration rate
135 ml/min/1.73 m2, Figure 1b, c and Table 1). On
presentation to the hospital, the patient appeared normal.
Physical examination was unremarkable with normal
growth; the height was 98.2 cm (þ 0.8 s.d., 68 percentile)
and weight was 13.0 kg (0.5 s.d., 38 percentile). There
was no dysmorphic features, edema, joint swelling, or
hearing loss. The systemic workup including
cardiovascular, neurological, and ophthalmological
examination was unremarkable. Renal sonogram
demonstrated normal-sized, symmetric kidneys
without hydronephrosis or cysts. Urological studies
including computed tomography were normal.
The renal biopsy obtained at 3 years of age
revealed glomeruli of normal size, with most
glomeruli only exhibiting mild segmental mesangial
cell proliferation (Figure 2a). There was no
glomerulosclerosis, tuft adhesions, or crescent formation
affecting glomeruli. There was no cellular infiltrates or
fibrosis evident in the tubulointerstitium or arterial
vessels.
Direct immunofluorescence revealed low-intensity,
granular staining of IgG, IgM, and C3 in the mesangium.
Electron microscopy demonstrated diffuse foot process
effacement, with occasional glomerular basement
membrane (GBM) alterations such as thinning, splitting,
and some mesangial deposits, there by excluding a
primary GBM or an immunocomplex disorder. Following
the biopsy, she still had persistent nephrotic-range
proteinuria (urine protein-to-creatinine ratio, 3.8 mg/mg),
although maintaining normal renal function. She was
treated with oral prednisone (1 mg/kg daily for 4 weeks),
but her proteinuria did not respond (Figure 1b). Because
of the unresponsiveness, cyclosporin (5 mg/kg daily)
was started in addition to alternate-day predonisone
(1 mg/kg). However, the proteinuria had still continued
and the immunosuppressants were subsequently tapered
off over the next 12 weeks. The patients had been
thereafter treated with supportive antiproteinuric therapy.
At 5 years of age, she still continued to have nephrotic-
range proteinuria (urine protein-to-creatinine ratio,
B4.0 mg/mg). To explore the pathological basis of SRNS, a
renal biopsy and genetic study was undertaken.
RENAL BIOPSY FINDINGS
The second biopsy undertaken at 5 years of age revealed eight
glomeruli that were all of normal size with no evidence of
segmental sclerosis, tuft adhesions, or crescents. Seven
glomeruli exhibited a mild segmental increase in mesangial
cells and matrix with narrowing or occlusion of the capillary
lumen (Figure 2b). A single glomerulus displayed pericap-
sular fibrosis. There was no tubular atrophy, interstitial
fibrosis, or cellular infiltration. Arterial vessels were un-
remarkable. Immunofluorescence studies revealed granular
staining of IgM (1þ grade) mainly in the mesangial area,
with some staining along capillary walls. Ultrastructural
examination revealed that the glomerular basement mem-
brane (GBM) generally displayed a normal appearance, with
segmental areas of thinning, irregular splitting, and multi-
lamination (Figure 2c). There were no global GBM changes
characteristic of Alport’s syndrome, and there were only
occasional electron-dense deposits in the mesangium, thereby
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excluding a primary GBM defect or an immunocomplex
disorder. Podocyte foot processes were diffusely effaced with
microvillus formation and vacuolization (Figure 2c). The
second biopsy at 5 years of age (Figure 2b) exhibited
histology of minimal changes with mild segmental mesangial
cell proliferation, essentially similar to that at 3 years of age
(Figure 2a). Immunohistochemical staining of podocin
demonstrated a linear but irregular pattern along the
glomerular capillary loops, with an intensity that varied
considerably from one segment to another. Mesangial cells
were preferentially increased in the lesions where the podocin
signal was totally lost, suggesting that the mesangial cell
proliferation occurs in association with podocyte injury
(Figure 2d).
CLINICAL DIAGNOSIS
The lack of definite sclerotic lesions in two biopsy specimens
suggests the possibility of minimal-change disease (MCD) or
focal segmental glomerulosclerosis (FSGS). Scattered IgM/C3
deposits can be seen in either MCD or FSGS. Irregularity or
loss of the podocin staining may reflect disturbed structural
integrity of the foot processes, but such patterns could be
seen in both FSGS and MCD. Despite the steroid resistance,
the patient takes a favorable clinical course and renal survival.
These observations favor the possibility that this patient
represents an MCD-like phenotype. The histopathological
diagnosis of FSGS depends upon the identification of
glomerular scarring affecting some glomeruli (focal) and
only some parts of the tuft (segmental). Therefore, an FSGS
lesion might have been missed in sampling (only eight
glomeruli), and the absence of typical segmental sclerosis
does not definitively exclude a diagnosis of an ‘under-
sampled’ FSGS.
Minimal-change disease and FSGS are a heterogeneous
clinicopathological group of diseases resulting from varying
etiologies. Admission laboratory workup at age 3 revealed no
hematological abnormalities (Table 1). There is no past
history of medications. The serological tests for autoanti-
bodies, serum cryoglobulin, rheumatoid factor, and several
virus were negative, and serum complement levels were
normal. In light of these observations, steroid-resistant
nephrotic syndrome (SRNS) in this patient appears to be a
primary event but not related with virus infection, drug-
induced, or immunocomplex diseases. Secondary FSGS due
to adaptive responses to loss of functioning nephrons is most
common in patients with obesity, unilateral kidney, sickle cell
disease, reflux nephropathy, and hypertensive nephrosclero-
sis. A renal ultrasound revealed normal-sized, symmetric
kidneys (8.5 cm long-axis length and 4–5 cm short-axis
width) with no evidence of urinary tract abnormalities.
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Figure 1 | Clinical features of SRNS patient. (a) Pedigree. Black symbol indicates the proband (arrow). There was no family history of
renal disease, dialysis, or transplant. (b) Clinical course. The patient (II-2) has no past medical history of infection and medication and her
growth and development were normal. She first manifested massive proteinuria and hematuria at 3 years of age. The nephrotic range
proteinuria persisted during the follow-up period and did not respond to the initial course of steroid therapy (prednisolone 1 mg/kg daily
for 4 weeks). Additional immunosuppressive regimen, consisting of oral predonisone (alternate-day 1 mg/kg daily) and oral cyclosporin
(5 mg/kg daily), was given and subsequently tapered off over the next 12 weeks. Two renal biopsies were performed at the ages of 3 and
5 years (arrowheads). (c) Her laboratory data at the onset (I), at the time of the second biopsy (II), and currently (III) are shown. The degree
of proteinuria was evaluated by a dipstick method, a standard quantitation (mg/100 ml), and a random urine protein-to-creatinine ratio
(Upr/cr, mg/mg). ACE-I; angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; hpf, high-power field.
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The history, laboratory investigation, and physical examina-
tion of this patient argue against a secondary glomerular
disorder.
The possibiltiy of genetic defects should be considered
even in nonfamilial SRNS cases because mutations in genes
affecting podocytes have been increasingly reported in
sporadic SRNS. No family history and the absence of
proteinuria in the parents led to an assumption that SRNS
occurs as a recessive defect of podocyte genes such as NPHS1
(nephrin),1 NPHS2 (podocin),2 NPHS3 (phospholipase C
epsilon-1, PLCE1),3 LAMB2 (laminin b2),4 or de novo
mutation in the dominant FSGS genes, including WT1,
LMX1B, TRPC6,4 and ACTN45 (Supplementary Table S1).
However, there are currently no specific, renal pathological
features that could distinguish genetic SRNS from other
general, nongenetic ones.6 Patients with podocin mutations
typically exhibit SRNS in earlier life (less than 3 years of age),
exhibit the renal histology of MCD or FSGS, and progress to
end-stage renal disease during childhood. Nephrin mutations
typically lead to severe congenital nephrotic syndrome of the
Finnish type, in which proteinuria develops in utero or soon
after birth. The glomeruli typically exhibit minimal histolo-
gical changes by light microscopy with irregular ‘microcystic’
dilation of the proximal tubules. PLCE1 mutations have been
recently reported in the Middle East families with early-onset
FSGS or diffuse mesangial sclerosis.3 The incidence of PLCE1
mutations and the pathological roles in glomerulosclerosis
remain to be investigated.
The patient had no dysmorphic features. She had normal
nails and patellae and a normal ophthalmological or
urological examination. On the basis of the clinical features,
mutations of WT1, LMX1B, and LAMB2 seem to be unlikely.
Moreover, ACTN4 and TRPC6 mutations are also less likely,
because these dominant genes typically lead to a late-onset
phenotype (Supplementary Table S1). This patient displayed
early-onset SRNS beginning proteinuria at the age of
3 years (Figure 1b, c and Table 1). Taken together, despite
no diagnostic FSGS lesions (Figure 2), podocin is the most
likely candidate gene and had been therefore tested first.
GENETIC AND MOLECULAR ANALYSIS
Sequencing of the podocin gene revealed that the patient is
a compound heterozygote for two missense mutations
of R168C and P271L (Figure 3a). Both mutations locate at
the carboxyl terminal part of podocin (Figure 3b). R168C has
been reported in European patients,7 whereas the P271L
mutation is novel. Although we were unable to examine the
genotype of her father, the healthy mother was a hetero-
zygous carrier of R168C, whereas the healthy brother had
no mutations, thereby suggesting a recessive mode of
segregation.
Expression studies with COS-7 cells demonstrated that
the R168C mutant protein exhibited a remarkable reticular
pattern, whereas the P271L mutant protein reached the
plasma membrane with some punctate aggregation scattered
over the cytoplasm (data not shown).
CLINICAL FOLLOW-UP
The patient has been followed up in the clinic for 2 years
and is now 7 years old. She remained nephrotic (protein-to-
creatinine ratio, 4.1 mg/mg), but her proteinuria had been
fairly controlled on dipyridamole and angiotensin-converting
enzyme inhibitor-I. The patient occasionally notes only trace
ankle edema but is otherwise doing well (Figure 1). Her renal
function is stable, with serum creatinine of 0.2 mg/100 ml
and the glomerular filtration rate estimated by the Schwartz
formula was 118 ml/min/1.73 m2. She exhibits normal growth
for her age according to the standard growth curve: a height
Table 1 | Laboratory data
Value (reference
range)
CBC
White blood cells 7.3 103/ml 4.5–7.0 103
Neutrophils 34% 40–70
Bands 1% 0–10
Lymphocytes 63% 22–44
Red blood cells 53.4 105/ml 35–50 105
Platelet 50.3 104/ml 15–35 104
Blood chemistry
Sodium 140 mmol/l 136–142
Potassium 3.8 mmol/l 3.5–5.0
Chloride 104 mmol/l 98–108
Urea nitrogen 11 mg/100 ml 9–29
Creatinine* 0.2 mg/100 ml o0.6
Total protein 5.3 g/100 ml 6.0–8.3
Albumin 3.1 g/100 ml 3.7–5.4
Cholesterol 279 mg/100 ml o170
Triglyceride 199 mg/100 ml 25–135
Urine
Urinalysis pH 5.5
Specific gravity 1.015
Blood 2+
Protein 3+ **
Urinary sediment RBC 20–30/hpf
WBC 1–4/hpf
1–5 hyaline and granular
casts/lpf
Immunological tests
C3 101.1 mg/100 ml 65–135
C4 15.0 mg/100 ml 13–35
CH50 37 U/ml 32–49
Antinuclear antibody Negative
Anti-neutrophil cytoplasmic
antibody
Negative
Anti-GBM antibody Negative
HCV antibody Negative
HBV antibody Negative
Cytomegalovirus antibody Negative
CBC, complete blood cell count; GBM; glomerular basement membrane; HBV,
hepatitis B virus; HCV, hepatitis C virus; hpf; high-power field; lpf; low-power field.
Laboratory data at the time of initial visit (age of 3 years) were shown. *An estimated
glomerular filtration rate was 135 ml/min/1.73 m2 body-surface area, the value
derived from the height index formula of Schwartz (Schwartz GJ, Pediatrics
58:259–263,1976).
**The random total protein-to-creatinine ratio (Upr/cr) was 4.0 (mg/mg) in the spot
urine specimen.
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of 129 cm (þ 0.2 s.d., 55 percentile) and a weight of 23 kg
(0.8 s.d., 30 percentile).
DISCUSSION
Clinical diagnosis of SRNS
This case demonstrates that the patient with podocin muta-
tions could present with an MCD-like phenotype in the
setting of an apparent prognostically favorable compound
heterozygote for the benign variants. The SRNS patient
report herein did not exhibit a diagnostic FSGS lesion in two
renal biopsies at the age of 3 and 5 years. SRNS patients may
exhibit various histological phenotypes including FSGS and
MCD with or without diffuse mesangial proliferation.
In a series of 55 SRNS children, 45% of the patients had
MCD, 48% had FSGS, whereas 7% had diffuse mesangial
proliferation.8,9 Clinically, patients thought to have MCD
with a poor response to immunosuppressive agents are likely
to have FSGS. Based solely on histology, it is difficult to
E P
C
*
*
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a c
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Figure 2 | Renal biopsy findings. (a) Renal histology at the age of 3 years displayed a minimal change pattern, which was nearly identical
to those at the age of 5 years (b). In both specimens, glomeruli typically have a mild, segmental mesangial cell hyperplasia that partially
narrows the capillary lumens (arrows). In some tufts lined with normal-appearing podocytes (arrowheads), the capillary lumens are still
patent (asterisks). The glomerular basement membrane (GBM) appears normal in thickness, contour, and texture. The interstitium, renal
tubules, and vessels are normal. (c) Electron micrograph at the age of 5 years. In podocytes, the majority of foot processes are diffusely
effaced. Some vacuolization (double arrows) and microvillous transformation (arrows) are noted. The GBM is essentially normal in
appearance, with only occasional thinning and irregular splitting (arrowheads). No discrete electron dense deposits are found in any area
surrounding the GBM. C, capillary lumen; E, endothelial cell, P, podocyte. (d) Immunohistochemical staining of podocin. Podocin is stained
as a strong, continuous linear pattern along the capillary loops, where the tuft architecture remains normal (arrowheads). By contrast, the
podocin signal exhibits a weak and discontinuous pattern in the areas of mesangial cell proliferation (arrows) (original magnification  400).
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distinguish between MCD and FSGS because a typical focal
sclerotic lesion may be missed in small renal biopsy samples as
was obtained in this case. This case of the patient with SRNS
exhibited mild segmental mesangial proliferation, with partial
obliteration of the capillary lumen, one pericapsular fibrosed
glomerulus, occasional GBM alterations (splitting and
lamellation), and scattered IgM/C3 deposits. It is of interest
that the glomeruli exhibited a mild increase in mesangial cell
number and matrix deposition. Mesangial cell proliferation
may be seen in isolation or in any combination with FSGS and
MCD as a histological variant of SRNS. It is unclear whether
mesangial alterations might represent a supervening, general
adaptive response to podocytopenia rather than being a truly
distinct disease entity.9 However, such intriguing possibility
has not been fully proven.
Genetic basis of SRNS
Our genetic testing revealed that the patient is a compound
heterozygote for the NPHS2 mutations of R168C and P271L.
NPHS2 mutations have initially been reported in children with
autosomal recessive, familial SRNS.2 The NPHS2 gene encodes
podocin, an integral membrane protein that has a hairpin-
loop intramembrane topology and is exclusively expressed at
the slit diaphragm (Figure 3c) .2 The biological role of podocin
is largely unknown. In light of the structural and functional
similarity to a raft-scaffolding protein caveolin, podocin
presumably plays a key role in sequestrating a selective set of
the slit diaphragm components, such as nephrin, CD2
associated protein (CD2AP), and ZO-1, thereby anchoring
the slit diaphragm complexes to the actin cytoskeleton. The
patients harboring podocin mutations typically exhibit early-
onset NS, with an average age ranging from 3 months to 3
years old, and rapidly progress to end-stage renal disease
before the age of 10. Our study indicated that the patient was a
compound heterozygote for the NPHS2 mutations of R168C
and P271L. Expression studies demonstrated that the R168C
mutant was trapped within the ER but the P271L mutant
reached the plasma membrane. The P271L mutant may have a
partially preserved function of scaffolding the slit diaphragm,
thereby accounting for the mild clinical course of the patient.
The absence of overt FSGS lesions and preserved renal
function until the age of 7 suggest that the combination of
two mutants defective in trafficking (R168C) or folding
(P271L) renders a relatively mild susceptibility to injury,
thereby requiring more time to develop a classic FSGS pattern.
NPHS2 mutations now have been shown to form a
spectrum of disease from early-onset SRNS to a slowly
progressive adult-onset FSGS.10 More than 30 of different
NPHS2 mutations, comprising missense mutations, frame-
shift, nonsense, splice site mutations, were found to segregate
the SRNS phenotypes.11 Recessive NPHS2 mutations are a
frequent cause of SRNS children.7,12,13 The large European
cohort studies have shown homo- or compound hetero-
zygous mutations in 30–40% and 10–20% of familial and
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Figure 3 | Mutational analysis of NPHS2 (podocin). (a) Mutations segregate in the recessive mode. Patient (II-2) is a compound
heterozygote for a maternal (a C-to-T transition leading to R168C) and possibly paternal allele (a C-to-T transition, causing P271L).
Segregation of R168C and P271L was checked by digesting the PCR products with BsmBI and NheI, respectively. R168C abolishes and P271L
creates a restriction digestion site in the PCR fragments, respectively (arrowhead; wild-type, arrow; mutant allele). The two mutations were
not found in any of the 140 control chromosomes. (b) Topology model of podocin and location of the mutations. The podocin protein
consists of 383 amino acids and has a hairpin-like intramembrane loop. An arginine residue at position 168 and a proline residue at position
271 locate at the carboxyl terminal of podocin. The arginine (red arrow head) and proline (green arrowhead) residues are evolutionarily
conserved across other distinct species, suggesting an essential role of these residues in protein structure and function.
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sporadic children with SRNS, respectively.7,12 Overall fre-
quency of the compound heterozygote for NPHS2 is
estimated to be 10–15% in a total number of SRNS children.
Occasionally, individuals with compound heterozygous
NPHS2 mutations associate with atypical mild, late-onset
disease, and post-transplantation recurrence.10,11 Some mis-
sense podocin mutations, for example, R229Q, P20L, have
only weak biological effects and act as a disease modifier or
risk factor predisposing to FSGS. Therefore, the individuals
harboring the mutations could display variable clinical
phenotypes (histology, severity, and age of onset), depending
upon the interplay among varying mutant alleles. In
comparison with the familial early-onset SRNS, NPHS2
mutations are less prevalent in adult-onset, sporadic FSGS.
A mutational screen with more than 500 cases of adult
idiopathic FSGS revealed only one compound heterozygous
NPHS2 mutation but no homozygous mutation.14,15 Taken
together, in comparison with the pediatric SRNS, recessive
NPHS2 mutations represent a rare cause of adult-onset
sporadic FSGS, the frequency being less than 1%. These
observations suggest that an etiology of FSGS in adults may
be more heterogeneous than that in children and that a
significant fraction of adult FSGS occur due to secondary
injury resulting from systemic diseases.
Clinical management and prognosis of SRNS patients
Optimum therapeutic strategies for SRNS are still contro-
versial and the regimens are practically optimized depending
upon the responsiveness and severity of the disease in each
patient. A strict control of proteinuria is the mainstay of
treatment, because numerous studies have shown that a
reduction of proteinuria or remission result in a better renal
outcome. Five-year renal survival rates in FSGS patients who
achieve remission are considerably high (94%). By contrast,
untreated nephritic-range proteinuria is a poor prognostic
sign, with up to 50% of patients progressing to end-stage
renal disease within 5–8 years.16 Immunosuppression is the
first line of therapy in SRNS patients, and its efficacy has been
confirmed in several trials; overall remission rates of up to
40–80% can be achieved with prolonged steroid treatment or
use of cyclosporine .17 By contrast, in patients with SRNS due
to the NPHS2 or WT1 mutations, immunosuppressive
therapy has not yet been proven to be clearly effective.12 In
light of possible steroid-adverse effects, immunosuppressive
therapy is not generally recommended for genetic form of
FSGS. In this case, immunosuppressive therapy was with-
drawn after 12–16 weeks of the initial trial at the age of
3 years, because of the unresponsiveness.
The patient is currently being treated with angiotensin-
converting enzyme inhibitor-I, angiotensin receptor blocker,
and dipyridamole. Renin–angiotensin axis blockade using
angiotensin-converting enzyme inhibitor-I and/or angioten-
sin receptor blocker has been increasingly used as an effective
adjunct for the treatment of SRNS children. Despite a relative
paucity of randomized control trial evidence in children,
these drugs have been shown to reduce proteinuria and
slower the rate of progression of chronic kidney disease in
adult. In cases of familial FSGS due to a genetic defect affecting
the slit diaphragm proteins, renoprotection is the only
treatment available. Early angiotensin inhibition successfully
induced a partial-to-complete remission in SRNS patients.18,19
Dipyridamole, anti-platelet agent, has been proven to be
beneficial to reduce the proteinuria in other glomerular
disease, as it prevents platelet deposition and subsequent
release of platelet-derived growth factor and lipid mediators
that promote glomerular damages. However, there are
only few data supporting a beneficial effect of dipyridamole
in nephrotic patients. A large, multicenter, randomized
clinical trial is warranted to evaluate the beneficial effects
and long-term outcome of these supportive therapies in SRNS
patients.
CONCLUSION
Focal segmental glomerulosclerosis represents a final histo-
pathological end point resulting from varying genetic and/or
nongenetic, environmental insults in glomeruli. Histological
phenotypes may vary with the severity of glomerular injury
and may reflect the underlying diverse etiologies.
This case illustrates the usefulness of genetic approaches to
explore the pathological basis for SRNS children. A screening
for the NPSH2 mutations is clinically important in nonres-
ponder children to an initial steroid therapy even in the
absence of family history. Such genetic information helps
clinicians to choose therapeutic options to reduce a risk of
unnecessary side effects. A genetic defect in podocyte slit
diaphragm complex and/or its anchorage to actin cytoske-
leton leads to FSGS. In this context, some researchers
proposed a new nosological approach, classifying certain
histological patterns with an etiological commonality invol-
ving podocyte injury as ‘podocytopathies’.5,20 Delineation of
the various forms of FSGS on the genetic basis may allow
better understanding of pathophysiology and improve
therapeutic approaches. The genetic testing will help guide
treatment decision to avoid a prolonged unnecessary steroid
therapy, even before obtaining a diagnostic FSGS lesion.
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